ArticleLiver cancer2022

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

James J Harding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.